Stock Scorer

Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics, Inc. reported revenue of 29.1M USD for the quarter ending 30 June 2026, down 2.1% from 29.7M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 29.1M -2.1%
Gross Profit Q3 '25 · ending 30 September 2025 28.9M +18.0%
Operating Income Q2 '26 · ending 30 June 2026 -14.4M —
Net Income Q2 '26 · ending 30 June 2026 -14.3M —
Cost of Revenue Q2 '26 · ending 30 June 2026 2.2M +91.9%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -16.7M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -17M —
Shares Outstanding Q2 '26 · ending 30 June 2026 100.6M -1.3%
EPS Q2 '26 · ending 30 June 2026 -0.17 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 116.6M11.5M9.9M-180K
20242024-12-31 105.8M16.2M17.9M-6M
20232023-12-31 113.5M-67.2M-85.5M17.4M
20222022-12-31 102.3M9.2M4.3M5.7M
20212021-12-31 7.3M-87.9M-87.9M-84.6M
20202020-12-31 20.9M-57.4M-56.2M—
20182018-12-31 6K-33.8M-30.1M-28.9M
20172017-12-31 1M-21.8M-21.6M-20M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3029.1M
Q1 '262026-03-3122.5M
Q4 '252025-12-3137.2M
Q3 '252025-09-3030.6M
Q2 '252025-06-3029.7M
Q1 '252025-03-3122.1M
Q4 '242024-12-3127.9M
Q3 '242024-09-3025.5M
Q2 '242024-06-3025.2M
Q1 '242024-03-3127.2M
Q4 '232023-12-3127.1M
Q3 '232023-09-3032M
Q2 '232023-06-3029.3M
Q1 '232023-03-3124.9M
Q1 '222022-03-31794K
Q4 '212021-12-312.4M
Q3 '212021-09-302.3M
Q2 '212021-06-301.1M
Q1 '212021-03-311.5M
Q4 '202020-12-312M

Gross Profit Quarterly

PeriodEndingGross Profit
Q3 '252025-09-3028.9M
Q2 '252025-06-3025.6M
Q1 '252025-03-3121.2M
Q4 '242024-12-3126.7M
Q3 '242024-09-3024.5M
Q2 '242024-06-3024.5M
Q1 '242024-03-3126.2M
Q4 '232023-12-3125.9M
Q3 '232023-09-3030.9M
Q2 '232023-06-3028.3M
Q1 '232023-03-3123.8M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-14.4M
Q1 '262026-03-31-9.4M
Q4 '252025-12-31118K
Q3 '252025-09-306.9M
Q2 '252025-06-30-2.2M
Q1 '252025-03-312.3M
Q4 '242024-12-31665K
Q3 '242024-09-304.2M
Q2 '242024-06-303.2M
Q1 '242024-03-318.1M
Q4 '232023-12-31-91.6M
Q3 '232023-09-3012.8M
Q2 '232023-06-305M
Q1 '232023-03-316.7M
Q4 '222022-12-31-22.5M
Q3 '222022-09-30-5.2M
Q2 '222022-06-3051.5M
Q1 '222022-03-31-14.7M
Q4 '212021-12-31-20.3M
Q3 '212021-09-30-25.2M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-14.3M
Q1 '262026-03-31-18.6M
Q4 '252025-12-311.2M
Q3 '252025-09-305.9M
Q2 '252025-06-30-2.2M
Q1 '252025-03-314.9M
Q4 '242024-12-31598K
Q3 '242024-09-302.9M
Q2 '242024-06-304.5M
Q1 '242024-03-319.9M
Q4 '232023-12-31-81.7M
Q3 '232023-09-307.5M
Q2 '232023-06-303.8M
Q1 '232023-03-314.2M
Q4 '222022-12-31-27.9M
Q3 '222022-09-30-4.9M
Q2 '222022-06-3051.6M
Q1 '222022-03-31-14.5M
Q4 '212021-12-31-20.3M
Q3 '212021-09-30-25.2M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-302.2M
Q1 '262026-03-311.2M
Q4 '252025-12-311.7M
Q3 '252025-09-301.6M
Q2 '252025-06-301.2M
Q1 '252025-03-31894K
Q4 '242024-12-311.2M
Q3 '242024-09-30958K
Q2 '242024-06-30770K
Q1 '242024-03-31979K
Q4 '232023-12-311.2M
Q3 '232023-09-301.2M
Q2 '232023-06-301.1M
Q1 '232023-03-311.1M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-16.7M
Q1 '262026-03-313.2M
Q4 '252025-12-31-5.6M
Q3 '252025-09-3014.2M
Q2 '252025-06-30-7.5M
Q1 '252025-03-31-129K
Q4 '242024-12-31-2.8M
Q3 '242024-09-301.7M
Q2 '242024-06-30-5.5M
Q1 '242024-03-312.9M
Q4 '232023-12-313.4M
Q3 '232023-09-307.6M
Q2 '232023-06-304.5M
Q1 '232023-03-3110.4M
Q4 '222022-12-3142.3M
Q3 '222022-09-30-7.3M
Q2 '222022-06-30-12.3M
Q1 '222022-03-31-12.1M
Q4 '212021-12-31-17.7M
Q3 '212021-09-30-21.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-17M
Q1 '262026-03-313M
Q4 '252025-12-31-5.8M
Q3 '252025-09-3013.6M
Q2 '252025-06-30-7.8M
Q1 '252025-03-31-251K
Q4 '242024-12-31-2.8M
Q3 '242024-09-301M
Q2 '242024-06-30-6.9M
Q1 '242024-03-312.7M
Q4 '232023-12-311M
Q3 '232023-09-305.6M
Q2 '232023-06-302.1M
Q1 '232023-03-318.7M
Q4 '212021-12-31-17.7M
Q3 '212021-09-30-22.1M
Q3 '202020-09-30-13.2M
Q2 '202020-06-30-15.2M
Q1 '202020-03-31-4.8M
Q4 '192019-12-31-8.1M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30100.6M
Q1 '262026-03-3191.3M
Q3 '252025-09-30104M
Q2 '252025-06-3089.2M
Q1 '252025-03-31102M
Q3 '242024-09-30102.6M
Q2 '242024-06-30102.2M
Q1 '242024-03-31102.6M
Q3 '232023-09-3078.9M
Q2 '232023-06-3078.9M
Q1 '232023-03-3178.9M
Q3 '222022-09-3031.5M
Q2 '222022-06-3031.5M
Q1 '222022-03-3131.5M
Q3 '212021-09-3031.4M
Q2 '212021-06-3031.3M
Q3 '132013-09-3033.6M
Q2 '132013-06-3033.6M
Q1 '132013-03-3133.6M
Q4 '122012-12-3133.6M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.17
Q1 '262026-03-31-0.08
Q4 '252025-12-310.02
Q3 '252025-09-300.00
Q2 '252025-06-30-0.02
Q4 '232023-12-31-1.41
Q3 '232023-09-30-0.89
Q2 '232023-06-30-1.10
Q1 '232023-03-310.52
Q4 '222022-12-310.03
Q3 '222022-09-300.38
Q2 '222022-06-30-0.26
Q1 '222022-03-31-2.54
Q4 '212021-12-31-2.87
Q3 '212021-09-30-3.11
Q2 '212021-06-30-3.04
Q1 '212021-03-31-3.36
Q4 '202020-12-31-2.85
Q3 '202020-09-30-3.10
Q2 '202020-06-30-3.43